NoopurSureshRajeMD

Director Center for Multiple Myeloma,Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston.

Join to view full profile

Dr. Raje is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Raje's full profile

Already have an account?

Office
55 Fruit St Yaw 7
Hematologyoncology
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0453

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2002
B.J. Medical College - University of PuneClass of 1989

Certifications & Licensure

MA State Medical License 2002 - 2025

Clinical Trials

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates Start of enrollment: 2007 Oct 01
Completed
Phase 2
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma Start of enrollment: 2008 Jun 01
Completed
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease Start of enrollment: 2012 Jun 01
Completed
Phase 1
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma Start of enrollment: 2012 Jul 12
Completed
Phase 1
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Start of enrollment: 2012 Nov 01
Completed
Phase 1
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01
Completed
Phase 2
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma Start of enrollment: 2014 Jul 15
Completed
Phase 1
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM Start of enrollment: 2017 Mar 07
Active, not recruiting
Phase 1
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2017 Jun 21
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
Blood. 2024-12-05
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2024-12-03
Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Recept...
Osnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, Omar Nadeem, Matthew J Frigault
Circulation. 2024-11-26

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Role of the RANK/RANKL Pathway in Multiple Myeloma
Noopur Raje, MD, Clinical Cancer Research
A Phase 1/2 Study of Evofosfamide, A Hypoxia-Activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Noopur S Raje, Ira Zackon, Clinical Cancer Research
Join now to see all

Abstracts/Posters

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteri...
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma
Noopur Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Noopur Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Hematologic Malignancies—Plasma Cell Dyscrasia
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Analysis of Hospitalization and Readmissions after CAR T Cell Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind,...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenstrom Macroglobulinemia, and Amyloidosis
60th American Society of Hematology Annual Meeting - 11/30/2018
Managing Multiple Myeloma: What's Next?
60th American Society of Hematology Annual Meeting - 11/30/2018
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Press Mentions

Hem/Onc Roundup: Dr. Raje Discusses Bone Disease in Myeloma Patients, and MoreJune 25th, 2021
Chimeric Antigen Receptor T-cell Therapy | Oncology Grand Rounds Series: Part 11 — Chimeric Antigen Receptor T-cell TherapyJune 3rd, 2021
Deeper Dives into the Bone Marrow Microenvironment of Myeloma Cells Provide New Insights into Novel Therapies and Disease BiologyMay 4th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member